David Hoang

Shares of Melinta Therapeutics Inc (NASDAQ: MLNT) shares were gaining more than 200% Wednesday, but a Jefferies analyst said the move is "overdone." The Analyst David Hoang maintained a Hold rating on Melinta Therapeutics with an unchanged $5 price target. The Thesis...